Compare VBIO & NIKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VBIO | NIKI |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3M | 1.5M |
| IPO Year | 2021 | 2018 |
| Metric | VBIO | NIKI |
|---|---|---|
| Price | $0.51 | $1.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 248.6K | 18.1K |
| Earning Date | 12-01-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $780,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $48.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.12 | $1.42 |
| 52 Week High | $812.50 | $10.39 |
| Indicator | VBIO | NIKI |
|---|---|---|
| Relative Strength Index (RSI) | 22.39 | 29.27 |
| Support Level | $0.47 | $1.42 |
| Resistance Level | $4.39 | $2.14 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | 0.60 | 0.11 |
| Stochastic Oscillator | 27.92 | 17.71 |
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
Niki BioSolutions Inc is a clinical-stage life sciences company focused on unmet medical needs and providing genomic and biomarker testing solutions to healthcare providers, research institutions, and life sciences organizations. Its activities include the development and application of proprietary technologies to support precision medicine across therapeutic areas including brain health and oncology. The company also collaborates with academic centers, disease foundations, and biopharmaceutical companies.